IP Library Granted Patent US 11,179,327
Granted Patent B2
US 11,179,327 · App. 16/106,730 · Granted Nov 23, 2021

Compositions and methods for the treatment of presbyopia

Inventors: Gerald Horn (Deerfield, IL); Lee Nordan (Dana Point, CA)
Assignee: LENZ THERAPEUTICS, INC.
A61K9/0048A61K9/08A61K31/439A61K31/4409A61K45/06A61K47/02A61K47/10A61K47/26A61K47/32A61K47/34A61K47/38A61P27/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,179,327
App. No.
16/106,730
Granted
Nov 23, 2021
Kind
B2
Abstract

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

Claims (15)

1. An ophthalmological composition for the treatment of presbyopia comprising from 0.225% to 1.85% w/v aceclidine as the only ophthalmologically active agent and one or more nonionic surfactants, wherein w/v denotes weight by total volume of the composition.

2. The composition of claim 1 , further comprising sodium chloride.

3. An ophthalmological composition for the treatment of presbyopia comprising from 0.225% to 1.85% w/v aceclidine as the only active agent, and a viscosity agent, wherein w/v denotes weight by total volume of the composition.

4. The composition of claim 3 , further comprising one or more nonionic surfactants at a total concentration from about 2% to about 7% w/v.

5. The composition of claim 4 , wherein the one or more nonionic surfactants are selected from the group consisting of a polysorbate, tyloxapol, a poloxamer, a cyclodextrin, d-α-tocopheryl polyethylene glycol 1000 succinate, a polyoxyl castor oil, a polyoxyl stearate, polyethylene glycol, a polyoxyethylene glycol alkyl ether and 2-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]ethanol.

6. The composition of claim 4 , wherein the one or more nonionic surfactants is a polysorbate.

7. The composition of claim 4 , wherein the one or more nonionic surfactants is polysorbate 80.

8. The composition of claim 3 , wherein the viscosity agent provides a viscosity of the total composition of about 25 centipoise or more at 25° C. and 0 shear.

9. The composition of claim 3 , wherein the viscosity agent provides a viscosity of the total composition from about 50 to about 10,000 centipoise or more at 25° C. and 0 shear.

10. The composition of claim 3 , wherein the viscosity agent provides a viscosity of the total composition from about 100 to about 5,000 centipoise or more at 25° C. and 0 shear.

11. The composition of claim 3 , wherein the viscosity agent provides a viscosity of the total composition from about 150 to about 450 centipoise or more at 25° C. and 0 shear.

12. The composition of claim 3 , wherein the viscosity agent is selected from the group consisting of a cellulose derivative, hyaluronate, a carbomer and a gum.

13. The composition of claim 3 , wherein the viscosity agent is selected from the group consisting of high molecular weight carboxymethyl cellulose, carbomer 940 and hydroxypropylmethyl cellulose.

14. The composition of claim 1 , wherein the composition is stable at temperatures from about 2 to about 8° C.

15. The composition of claim 3 , wherein the composition is stable at temperatures from about 2 to about 8° C.

Assignments (4)
CHANGE OF NAME Recorded Apr 2, 2024
From: LENZ THERAPEUTICS, INC.
To: LENZ THERAPEUTICS OPERATIONS, INC.
Reel/Frame 066978/0082 →
MERGER AND CHANGE OF NAME Recorded Sep 29, 2021
From: PRESBYOPIA THERAPIES, INC.; PRESBYOPIA THERAPIES, INC.
To: LENZ THERAPEUTICS, INC.
Reel/Frame 057671/0014 →
CHANGE OF NAME Recorded Nov 9, 2020
From: PRESBYOPIA THERAPIES, LLC
To: PRESBYOPIA THERAPIES, INC.
Reel/Frame 054363/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2020
From: HORN, GERALD; NORDAN, LEE
To: PRESBYOPIA THERAPIES, LLC
Reel/Frame 052849/0632 →
Continuity (15)
Continuation In Part 15864703 · Jan 8, 2018
Continuation In Part 15956936 · Apr 19, 2018
Continuation In Part 15864703 · Jan 8, 2018
Continuation In Part 15235431 · Aug 12, 2016
Continuation In Part 15073139 · Mar 17, 2016
Continuation In Part 14742903 · Jun 18, 2015
Continuation In Part 15073089 · Mar 17, 2016
Continuation In Part 14742903 · Jun 18, 2015
Continuation In Part 14223639 · Mar 24, 2014
Provisional Application 61938438 · Feb 11, 2014
Provisional Application 61917620 · Dec 18, 2013
Provisional Application 61904510 · Nov 15, 2013
Provisional Application 61882998 · Sep 26, 2013
Provisional Application 61871215 · Aug 28, 2013
Related Publication 20190000755A1 · Jan 3, 2019
Cited By (3)
US 12,414,942 US 12,533,347 US 12,653,779